Keymed Biosciences Inc. (HKG:2162)

Keymed Biosciences Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	418.41	851.03	604.07	1,521	199.41
Short-Term Investments	1,737	1,694	2,339	1,951	144.28
Trading Asset Securities	0.24	174.37	232.19	53.4	10.39
Cash & Short-Term Investments	2,156	2,719	3,175	3,525	354.08
Cash Growth	-20.73%	-14.37%	-9.91%	895.41%	-29.04%
Accounts Receivable	62.85	27.97	0.48	10.55	-
Other Receivables	-	18.5	34.01	0.72	0.84
Receivables	62.85	46.47	34.49	11.27	0.84
Inventory	111.42	61.1	51.33	22.43	11.33
Restricted Cash	-	1.78	-	-	-
Other Current Assets	136.14	111	48.83	23.67	14.66
Total Current Assets	2,466	2,940	3,310	3,582	380.92
Property, Plant & Equipment	1,048	893.74	584.43	177.53	124.82
Long-Term Investments	210.03	21.63	20.57	20.28	-
Other Intangible Assets	9.75	1.11	1.5	1.1	0.11
Other Long-Term Assets	32.66	26.91	15.84	153.59	24.1
Total Assets	3,767	3,883	3,932	3,934	529.95
Accounts Payable	26.01	29.49	14.91	2.78	3.42
Accrued Expenses	-	110.33	90.99	49.93	15.31
Short-Term Debt	-	105.04	60.79	0.55	42.37
Current Portion of Long-Term Debt	472.37	-	0.6	-	-
Current Portion of Leases	12.36	19.43	11.08	11.72	4.18
Current Income Taxes Payable	-	1.82	1.03	0.94	0.16
Current Unearned Revenue	1.58	-	-	1.61	10.87
Other Current Liabilities	235.41	48.08	200.3	44.54	3.93
Total Current Liabilities	747.73	314.18	379.7	112.08	80.24
Long-Term Debt	257.19	331.83	28.8	-	1,386
Long-Term Leases	11.32	21.62	20.93	26.99	20.31
Long-Term Unearned Revenue	274.78	228.19	163.67	8.72	6.79
Long-Term Deferred Tax Liabilities	0.35	0.28	-	-	-
Other Long-Term Liabilities	-	-	-	141.29	131.64
Total Liabilities	1,291	896.11	593.1	289.07	1,625
Common Stock	0.17	0.17	0.17	0.17	0.05
Additional Paid-In Capital	-	8,484	8,485	8,516	-
Retained Earnings	-	-5,649	-5,290	-4,982	-1,095
Treasury Stock	-0	-	-	-	-
Comprehensive Income & Other	2,474	151.76	144.97	116.82	-
Total Common Equity	2,475	2,986	3,340	3,651	-1,095
Minority Interest	0.64	0.5	-1.07	-5.59	-0.27
Shareholders' Equity	2,475	2,987	3,339	3,645	-1,095
Total Liabilities & Equity	3,767	3,883	3,932	3,934	529.95
Total Debt	753.24	477.92	122.19	39.26	1,453
Net Cash (Debt)	1,402	2,241	3,053	3,485	-1,099
Net Cash Growth	-37.43%	-26.59%	-12.40%	-	-
Net Cash Per Share	5.35	8.58	11.69	21.67	-16.37
Filing Date Shares Outstanding	262.34	276.6	277.39	279.74	271
Total Common Shares Outstanding	262.34	276.6	277.39	279.74	271
Working Capital	1,718	2,625	2,930	3,470	300.68
Book Value Per Share	9.43	10.80	12.04	13.05	-4.04
Tangible Book Value	2,465	2,985	3,339	3,650	-1,095
Tangible Book Value Per Share	9.40	10.79	12.04	13.05	-4.04
Buildings	-	190.16	-	-	-
Machinery	-	626.77	235.49	110.64	82.14
Construction In Progress	-	34.48	323.55	21.63	0.18
Leasehold Improvements	-	60.77	51.73	42.45	42.68

Updated Sep 23, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.